Skip to main content
  • Paul Scherrer Institut PSI
  • PSI Research, Labs & User Services

Digital User Office

  • Digital User Office
  • DE
  • EN
  • FR
Paul Scherrer Institut (PSI)
Suche
Paul Scherrer Institut (PSI)

Hauptnavigation

  • Our ResearchOpen mainmenu item
    • Current topics from our research
    • Matter and Material
    • Human Health
    • Energy and Environment
    • Large Research Facilities
    • Brochures
    • 5232 — The PSI magazine
  • IndustryOpen mainmenu item
    • Overview
    • Technology Transfer
    • Expertise
    • Spin-off Companies
    • Park Innovaare
  • Proton TherapyOpen mainmenu item
    • Overview
    • Physician & Patient Information
  • CareerOpen mainmenu item
    • Overview
    • Job Opportunities
    • Working at PSI
    • Personnel Policy
    • Training and Further Education
    • Vocational Training
    • PSI Education Centre
    • Support Program "PSI Career Return Program"
    • PSI-FELLOW/COFUND
  • Visit to PSIOpen mainmenu item
    • Overview
    • Visitor Centre psi forum
    • Schülerlabor iLab
    • Public Events
    • How to find us
  • About PSIOpen mainmenu item
    • PSI in brief
    • Strategy
    • Guiding principles
    • Facts and figures
    • Organisational structure
    • Für die Medien
    • Suppliers and customers
    • Customers E-Billing
    • Contact
  • DE
  • EN
  • FR

Digital User Office (mobile)

  • Digital User Office

You are here:

  1. PSI Home
  2. Industry
  3. Debiopharm: New generation radionuclide therapy in the fight against lung cancer

Secondary navigation

Industry

  • Technology Transfer News
  • Technology Transfer
    • PSI as Transfer Partner
    • Offers of Transfer Office
    • Intellectual Property
    • The team of technology transfer
  • Expertise
  • Companies
    • Advanced Accelerator Technologies
    • Alme AG
    • Basilea Pharmaceutica International Ltd.
    • CEKAtec AG
    • CCI AG
    • MDC Max Daetwyler AG
    • DECTRIS AG
    • FHNW
    • Ferrovac Gmbh
    • Inspire AG
    • IOxOS Technologies
    • Kunz precision AG
    • Lehner AG
    • Methanol Casale
    • Metrolab Technology
    • TEL Mechatronics Ltd.
    • Rolic Technologies Ltd.
    • SwissNeutronics AG
    • TOFWERK AG
    • Trüb AG
  • Spin-off Companies
  • Park Innovaare
  • Useful links

  • Terms and Conditions
  • Suppliers Portal
10 September 2020

Debiopharm: New generation radionuclide therapy in the fight against lung cancer

Debio 1124 - a compound developed at PSI and out-licensed to the Swiss company Debiopharm - is being tested in a clinical phase I study in patients with small cell lung cancer, as Debiopharm has published in a press release. The peptide binds highly specifically to proteins found on tumour cells in this type of cancer. If Debio 1124 is coupled to a nuclide, it can be used both to detect the tumour with imaging procedures and therapeutically to destroy the tumour cells bound in this way.

https://www.debiopharm.com/drug-development/press-releases/debiopharms-new-generation-radionuclide-therapy-advances-into-clinical-research-in-the-fight-against-lung-cancer/
From the Laboratory to the Clinic: PSI-researcher at work.
From the Laboratory to the Clinic: PSI-researcher at work.

Sidebar

top

Footer

Paul Scherrer Institut

Forschungsstrasse 111
5232 Villigen PSI
Switzerland

Telephone: +41 56 310 21 11
Telefax: +41 56 310 21 99

How to find us
Contact form

Visitor Centre psi forum
School Lab iLab (in German)
Center for Proton Therapy
PSI Education Centre
PSI Guest House
PSI Gastronomie (in German)

 

Service & Support

  • Phone Book/People Search
  • User Office
  • Accelerator Status
  • PSI Publications
  • Suppliers
  • E-Billing
  • Computing
  • Safety (in German)

Career

  • Working at PSI
  • Job Opportunities
  • Training and further education
  • Vocational Training (in German)
  • PSI Education Center

For the media

  • PSI in brief
  • Facts and Figures
  • Media Contact
  • Media Releases
  • Social Media Newsroom

Follow us: Twitter (in English) LinkedIn Youtube Issuu RSS

Footer legal

  • Imprint
  • Terms and Conditions
  • Editors' login